Robert L. Coleman, MD, on Ovarian Cancer: Results From an NRG Oncology/Gynecologic Oncology Group Trial
2018 ASCO Annual MeetingRobert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on secondary surgical cytoreduction followed by platinum-based combination chemotherapy, with or without bevacizumab, in platinum-sensitive, recurrent ovarian cancer (Abstract 5501).
Related Videos
Jeremy S. Abramson, MD, on Non-Hodgkin Lymphoma: Results From the TRANSCEND NHL 001 Trial
Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).
Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial
Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for...
Apostolia-Maria Tsimberidou, MD, PhD, on Precision Medicine: Results From the IMPACT Study
Apostolia-Maria Tsimberidou, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses findings on clinical outcomes, including long-term survival, according to the ...
Jed A. Katzel, MD, on Head and Neck Cancer: Findings on Treatment of Female Patients
Jed A. Katzel, MD, of Kaiser Permanente, discusses his team’s findings on the disparities in head and neck cancer treatment for women and the possible missed opportunities to take ...
Peter Hillmen, MB, ChB, on CLL: Results From the MURANO Trial
Peter Hillmen, MB, ChB, of St James’s University Hospital, discusses phase III study findings on minimal residual disease negativity with venetoclax plus rituximab in relapsed or r...
